Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310003, China.
Breast Center, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310003, China.
Cell Death Differ. 2018 Feb;25(2):406-420. doi: 10.1038/cdd.2017.176. Epub 2017 Nov 10.
Chemoresistance often leads to the failure of breast cancer treatment. MicroRNAs (miRNAs) play an important role in the progression and chemoresistance of cancer. However, because of the complexity of the mechanisms of chemoresistance and the specificity of miRNA regulation in different cell types, the function of miR-20a in breast cancer chemoresistance is still unclear. Here, by using miRNA microarray and high-content screening techniques, we found that miR-20a/b were significantly downregulated in breast cancer tissues compared with normal breast tissues, and low miR-20a/b expression was correlated with poor survival in breast cancer patients. Ectopic overexpression of miR-20a sensitized breast cancer cells to a broad spectrum of chemotherapy drugs and suppress their proliferation both in vitro and in vivo. Further study demonstrated that miR-20a directly targeted the 3'untranslated region of MAPK1, and thus downregulated the expression of P-gp and c-Myc by inhibiting the MAPK/ERK signaling pathway, whereas c-Myc can bind to the promoter region of the miR-20a gene to promote the expression of miR-20a. Together, our study identified a novel miR-20a/MAPK1/c-Myc feedback loop that regulates breast cancer growth and chemoresistance. These findings suggest that miR-20a synergizing with anticancer drugs will be a promising treatment strategy, especially for chemoresistant patients.
化疗耐药常常导致乳腺癌治疗失败。microRNAs(miRNAs)在癌症的进展和化疗耐药中发挥重要作用。然而,由于化疗耐药机制的复杂性以及 miRNA 在不同细胞类型中的调控特异性,miR-20a 在乳腺癌化疗耐药中的功能仍不清楚。在这里,我们通过使用 miRNA 微阵列和高内涵筛选技术,发现 miR-20a/b 在乳腺癌组织中与正常乳腺组织相比显著下调,并且低表达 miR-20a/b 与乳腺癌患者的不良预后相关。miR-20a 的异位过表达使乳腺癌细胞对广泛的化疗药物敏感,并在体外和体内抑制其增殖。进一步的研究表明,miR-20a 直接靶向 MAPK1 的 3'非翻译区,从而通过抑制 MAPK/ERK 信号通路下调 P-gp 和 c-Myc 的表达,而 c-Myc 可以结合 miR-20a 基因的启动子区域促进 miR-20a 的表达。总之,我们的研究确定了一个新的 miR-20a/MAPK1/c-Myc 反馈环,调节乳腺癌的生长和化疗耐药性。这些发现表明,miR-20a 与抗癌药物联合使用将是一种有前途的治疗策略,特别是对于化疗耐药的患者。